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Breast cancer metastases to the neurocranium might involve the bone, the dura, or the brain parenchyma. The latter location
is the far most common. The annual incidence of brain metastases in patients with breast cancer is in the range of 4–11 per
100.000 persons per year. Symptoms and ﬁndings mainly result from the location of the lesion. The diagnostic method of choice is
magnetic resonance imaging before and after administration of contrast material. Breast cancer brain metastases present as solid,
cystic, or partially cystic lesions with marked contrast enhancement and perilesional edema. The therapeutic option of choice is
microsurgical resection whenever possible. Adjuvant treatment includes radiotherapy, radiosurgery, and/or chemotherapy.
1.Introduction
Breast cancer metastases to the neurocranium may involve
the bone, the dura, or the brain parenchyma. The latter is
the most common location. Aﬀected patients are often in
an advanced stage of disease [1]. According to advances in
treatment of primary tumors, the amount of patients eligible
for surgery is rising.
As early as in 1889, Stephen Paget showed that “the
distribution of the secondary growths is not a matter of
chance.” Based on autopsy ﬁndings in 650 patients with
breast cancer, he described aﬀection of the cranium in 36
cases, whereas there was no single case of metastasis to the
hand or feet [2]. It is an important clinical observation
that tumors exhibit a predilection to metastasize to certain
organs.Currentresearchhasaddressedthemolecularprocess
of the metastatic cascade: (a) migration from the primary
tumor, (b) dissemination into and survival in the blood
vessels, (c) extravasation, and (d) proliferation at a distant
site as well as the importance of the tumor-host interface
[3–5].
In the ﬁrst section of this paper, the general terms of
neurosurgical treatment of metastases to the neurocranium
from solid tumors are presented. In the second section,
special issues of brain, bone, and dural metastases from
breast cancer are discussed.
2. General Terms of Neurosurgical Treatment of
Metastasestothe Neurocranium
2.1. Clinical Examination. Diagnostic workup includes a
complete neurological examination and evaluation of the
extent of the primary tumor as well as comorbidity. Bone
metastasesmightbedetectedbybulkingofthecalvaria.Brain
metastases often lead to hemiparesis, ataxia, and aphasia [6].
Neurological examination can also give clues for possible
spinal involvement. These patients might show ataxia and
paresis and complain about radicular pain or sensation
deﬁcits.
2.2. Imaging. Magnetic resonance imaging (MRI) is useful
for detecting small intraparenchymal lesions down to 1mm
diameter. Concerning this issue, MRI is highly superior
to computed tomography (CT). Furthermore, MRI can
suﬃciently detect leptomeningeal spread and small dural
lesions. It is very useful in detecting dural involvement in
patients with bone or brain metastases. This information is
important for surgery. MRI is usually generated in a sagittal,
coronal, and axial view.
CT is useful in determining the extent of bone destruc-
tion, either in bone metastases or in bone involvement
resulting from metastases to the dura or brain.2 Pathology Research International
Scintigraphy is used for screening purposes. If metastasis
to the skull is suspected, CT scan should follow. If metastasis
to the brain is suspected, MRI should follow.
Figure 1 shows examples for imaging results in patients
with breast cancer metastases to the neurocranium.
2.3. Neuronavigation. Nowadays, preparation for surgery
includes neuronavigation for most cases of intracranial
tumors. Neuronavigation is a 3D computer model of the
patient’s head which can be used intraoperatively as a
reference location system. Basically, a thin-slice MRI or CT
scan is performed after reference markers have been applied
to the patient’s head (ﬁducial markers) .T h e2 Dd a t as e ti s
transferred to a working station and processed into a 3D set.
Immediately before starting the operation, the position of
the patient’s head is registered to the system in relation to
a reference star. Thus, the surgeon can control the location of
a pointer tip intraoperatively. Neuronavigation is helpful in
minimizing the approach to the tumor. In glioma surgery,
it is also useful for resection control. It must be noticed
that intracranial structures are “shifting” after opening of the
skull and again after resection of intracranial lesions. This
incident is called brain shift.
3. Breast Cancer Metastasesto
the Neurocranium
3.1. Skull Metastases. T h er a t eo fh e m a t o g e n o u ss k u l lm e t a s -
tases, even though it is low in comparison to brain metas-
tases, is higher in breast cancer than in many other tumors
[7]. Hopkins et al. have described that bone metastases were
detected by 99mTc scintigraphy in approximately 50% of
breast cancer patients in an early stage of the disease [8].
However, most of the lesions do not become symptomatic.
It can be estimated that they grow slowly allowing other
complications of the underlying breast cancer to develop.
Most patients present with local swelling, sometimes accom-
panied by local pain. Neurological deﬁcits are infrequent
at the time of presentation. Bone metastases may reach
signiﬁcant size until they become symptomatic and, thus,
until they are diagnosed. Metastases of the calvaria are often
noted by the patient or by the patients family as swelling
[9, 10]. Skull base metastases may become symptomatic by
diplopia and/or exophthalmia when the orbit is involved.
CT is required for visualization of the extent of bone
destruction. MRI is superior to CT in detecting inﬁltration
of the dura and neural tissue. Thus, both techniques are
required preoperatively. Surgery should be considered when
(1) a neurological deﬁcit is present and/or (2) massive
destruction of bone (and dura) occurs, (3) when there is
a painful mass, (4) when solitary metastasis is present, or
(5) when conﬁrmation of the diagnosis is warranted [10].
Surgery aims to resect the inﬁltrated bone and replace it
by bone-cement (cranioplasty). Alternatively, a titan mesh
may replace the bony defect. This is especially useful in
complex lesions involving the skull base. If the dura is
inﬁltrated, it needs to be both resected and replaced The
diﬀerential diagnosis of skull metastases includes primary
skull tumors (e.g., osteoma, chondrosarcoma, chordoma,
dermoid, and epidermoid cysts) and benign tumor-like
lesions (e.g.,ﬁbrousdysplasia,hyperostosis,andeosinophilic
granuloma) [10].
3.2. Dural Metastases. Dural metastases are uncommon.
According to a postmortem series of 27 patients, breast
cancer was the second most common malignancy to cause
duralmetastases.Themostfrequentcancertypewasprostate
cancer. The third most common type was cervical cancer
[11]. Dural metastases may become symptomatic as solid
masses or as metastatic subdural ﬂuid collection, assembling
a chronic subdural hematoma. Dural metastases are an
important diﬀerential diagnosis of meningioma and must be
suspected in every patient with chronic subdural hematoma
and underlying malignant disease [12–14]. When solid dural
metastases are removed, the dura is incised circumferentially
around the lesion. Then, the tumor is dissected from
the brain tissue with cottonoids and gentle coagulation.
Retraction of the brain should be avoided. Accompanying
veins should be preserved. After circumferential dissection,
the tumor can be gently removed. The dura has to be
replaced by autologous graft tissue or artiﬁcial material. The
intraoperative aspect of dural metastases is quite similar to
that of meningioma. Histological examination is essential to
clarify the diagnosis.
3.3. Brain Metastases
3.3.1. Epidemiology. Breast cancer is the second most com-
mon solid tumor that forms brain metastases. The most
common tumor type is lung cancer. The annual incidence of
breast cancer brain metastases in USA is in the range of
5–10 per 100.000 per year. Altogether, 10–15% of patients
with metastatic breast cancer will develop brain metastases
during the course of the disease. The median age at time
of diagnosis of breast cancer is 47 years. The mean latency
between diagnosis of breast cancer and the detection of
breast cancer brain metastases is 2-3 years. However, brain
metastases may occur even as long as 20 years after diagnosis
of breast cancer [1, 6, 15].
3.3.2. Location and Symptoms. Brain metastases character-
istically grow at the white/gray matter border. They are
more frequently located in the supratentorial than in the
infratentorial space. Symptoms depend on the size and the
exact location of the lesion. Even small lesions may cause
neurological deﬁcits if they grow inside or close to eloquent
brain areas as the motor area or the speech regions. Large
lesions may cause mass eﬀect by increasing the intracranial
pressure or by blocking cerebrospinal ﬂuid (CSF) pathways
causing hydrocephalus. According to our own data including
47 patients, the most frequent symptoms at the time of pres-
entation to a neurosurgical unit were ataxia (23%), headache





Figure 1: (a)–(c) 77-year-old femal with aphasia resulting from breast cancer dural metastasis, (a) preoperative T1-weighted MRI showing
contrast enhancement of a left parietal dural tumor. (b) Preoperative CT scan shows bone erosion (arrow). (c) Postoperative CT scan
documents the removal of the dural mass and the inﬁltrated bone which has been substituted by bone cement cranioplasty. (d) T1-weighted
MRI showing contrast-enhancing breastcancer skullbase metastasis in the clival region occurring ina 45-year-old female with known breast
cancer and diplopia (arrow). (e, f) MRI of a 69-year-old female with right occipital breast cancer brain metastases. (e) T1-weighted MRI
shows a ring-like contrast-enhancing lesion (arrow). (f) T2-weighted MRI shows the lesion with signiﬁcant peritumoral ﬁnger-like edema
(arrows).
vertigo (11%) [6, 16]. In few cases, brain metastases are
incidental ﬁndings during staging procedures.
In 2005, we published a series of 177 consecutive patients
who underwent craniotomy for newly diagnosed brain
metastases from various tumors. Following lung cancer,
breast cancer was the second most common origin of brain
lesions.Colorectalcancerandrenalcancerwerethethirdand
fourth most common origins. The amount of solitary brain
lesions (only detectable distant metastases in the body) was
26% in breast cancer lesions whereas it was 72% in nonsmall
cell lung cancer (NSCLC), 29% in colorectal cancer (CRC),
and 56% in renal cancer (RC). Extracranial metastases
were present in 54% of breast cancer patients versus 45%
in NSCLC, 59% in CRC, and 33% in RC. Synchronous
diagnosis of the primary tumor and brain metastasis is very
uncommon in breast cancer (3%, 1 patient). In contrast, it is
common in NSCLC (54%) and CRC (59%). It is uncommon
in renal cancer (11%) [6].
3.3.3. Prognostic Indicators. Overall, accepted indicators
of prolonged survival are only younger age and good
patient performance. There is no uniform deﬁnition of
elderly patients with brain metastases. Usually, the threshold
between younger and elderly individuals is set somewhere
between 50 and 75 years [17–19]. In a systematic statistical
evaluation, we could deﬁne the age threshold relevant for
prognostic diﬀerences as 65 years [16]. Patient performance
is usually documented as Karnofsky performance score
(KPS) as described by Karnofsky and Burchenal, in 1949
[18, 19]. Usually, a KPS of 70 or higher is regarded as
favorable and is often required for the inclusion of patients
into treatment studies.
For clinical decision making, additional factors are taken
into account. Herein, local control of the primary tumor
is an important factor as well as the extent of extracranial
metastases and the number of intracranial metastases [20–
22]. Figure 2 shows the survival curve of 47 patients who4 Pathology Research International
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Figure 2: Kaplan Meier plots depict survival of 47 patients with
breast cancer brain metastases who underwent surgical resection
and adjuvant radiotherapy in our department between 1994 and
2004. 42 patients had one brain metastases, 4 patients had 2
intraparenchymal lesions, and 1 patient had 3 metastases. Median
survival was 205 days = 29 weeks.
underwent surgery for breast cancer brain metastases in our
department in a 10-year interval.
3.3.4. Imaging. The standard imaging technique for the
detection of brain metastases is MRI before and after the
administrationofcontrastmaterial.Herein,brainmetastases
appear as ring-like, solid or partially solid/cystic contrast-
enhancing lesions in T1-weighted imaging. The surrounding
edema, which is often signiﬁcant, can be best visualized
in the T2-weighted image. It is a ﬁnger-like edema of the
white matter. MRI is highly superior to (CT) in detecting
small lesions down to 1mm diameter. CT is adequate for the
emergency situation and should be followed by MRI once
brain metastases are suspected. Infrequently, patients with
brain metastases present with acute, stroke-like symptoms
caused by intratumoral bleeding. This condition is relatively
frequent in renal cancer and malignant melanoma but may
also occur in individuals with breast cancer.
3.3.5. Surgery: Indications and Techniques. The goal of
surgery in patients with brain metastases is to establish the
diagnosis and relieve mass eﬀect. If brain metastases are
accessible, they should be completely removed. Currently,
thereisevidencethatbrainmetastases,likegliomas,createan
inﬁltration zone involving the adjacent brain parenchyma. It
will be up to further studies to generate treatment decisions
from this observation.
Randomized prospective data concerning the surgical
treatment of patients suﬀering from brain metastases are
only available for patients with single brain lesions. Herein,
it has been proven that surgery plus radiotherapy (external
beam radiation) is superior to radiotherapy alone in pro-
longing patient’s survival [23, 24].
Suﬃcient data for patients with multiple metastases are
lacking.Fromtheexistingliterature,itcanbeassumedthatin
patients with 1–3 brain lesions open microsurgical resection
should be considered whenever possible. In this situation,
surgical intervention is indicated in patients who present
with (1) a primary tumor under control, (2) accessible brain
lesions, and (3) a total number of brain metastases of at least
3[ 18, 19]. As a rule of thumb, patients undergoing surgical
resection of brain metastases should have a life expectancy
of at least 6 months. However, occasionally, patients with
multiple brain metastases present with one life-threatening
lesion. This lesion might be resected in an emergency opera-
tioninordertopreventsuddenpatientdeath.Ingeneral,due
to advances in operative techniques and neuroanesthesia,
the removal of 1–3 brain metastases in 1-2 operations is
appropriate. Small lesions (≤3cm diameter, ≤3 metastases
in total) might be treated by stereotactic radiosurgery as
an alternative to open surgery or as additional treatment
[6, 18, 19, 25].
In patients with multiple metastases, it has been shown
that radiotherapy plus radiosurgery is superior to radio-
surgery alone. As a consequence, radiosurgery should not be
performed as single therapeutic method [26].
Preparation for surgery includes the selection of the
approach which is in most times neuronavigation. Corticos-
teroids should be given to prevent or reduce brain swelling.
The patient’s head is placed in a rigid ﬁxation system
to prevent unwanted movement during the operation.
Neuronavigation-guided skin incision and bone trepanation
is performed. In superﬁcial metastases, the dura should be
inspected for possible inﬁltration. Inﬁltrated dura needs to
be replaced. The intracranial part of the operation is carried
out using the operative microscope. After dural opening, the
metastasis is accessed and dissected from the surrounding
brain tissue. In larger lesions, it may be necessary to
partly remove the lesion before dissecting it. Frozen sections
may be performed for intraoperative histology. Completely
removing the metastasis without damaging the adjacent
brain tissue should always be the goal. After removal of the
lesion, meticulous hemostasis is performed by cauterization
followedbytheapplicationofcellulosestrips.Afterirrigation
with saline, the dura is closed and the bone ﬂap is placed
and ﬁxed. Tissue specimens are sent to histopathology for
deﬁnitive diagnosis.
3.3.6. Complications of Surgery. Brain metastases tend to
cause brain swelling which can be treated by steroids and
osmotic diuresis. Steroids should be continued over a few
days after surgery and should then be reduced over some
days before they are tapered. Prophylactic antibiotics can
reduce infection. Careful microsurgical dissection prevents
injury to the brain tissue and to small veins thus preventing
unfavorable neurological outcome. Speciﬁc complications
of surgery include intracranial bleeding (intraparenchymal,
epidural, subdural), subtotal resection (if it is not primarily
wanted), injury to eloquent brain areas and cerebrospinal
ﬂuid ﬁstula. In patients who have had seizures prior to
surgery, anticonvulsants should be given. Postoperatively,
specialcareshouldbetakentopreventdeepveinthrombosis.
3.3.7. Complications of Brain Metastases: The Course of
the Disease. As many as 50% of patients will suﬀer from
brain metastasis recurrence—either at the site of the treated
metastasis or anywhere else within the brain. Reoperation isPathology Research International 5
possible. However, most patients fail to qualify for repeated
surgery due to poor performance.
Patients with breast cancer brain metastases tend to
develop leptomeningeal dissemination (leptomeningeal car-
cinomatosis) more often than patients with brain metastases
of other origin. Leptomeningeal spreading is caused by dis-
semination of tumor cells via the cerebrospinal ﬂuid (CSF).
It is best visualized with contrast-enhanced MRI. Treatment
might consist in intrathecal chemotherapy given via an
implanted reservoir. Herein, methotrexate is commonly used
[27]. Radiotherapy might be an alternative or additional
palliative option [28].
3.3.8.AdjuvantTreatment. Radiotherapyisappliedonarou-
tine basis after surgical resection. Radiosurgery is an option
for small lesions (≤3cm diameter) either as an alternative to
open resection or as additional treatment.
Chemotherapy for brain metastases is mostly targeted
at the primary tumor. Delivering systemic chemotherapy
to brain metastases is highly limited by the presence of
the blood-brain barrier. Recent evidence highlights the
importance of the alkylating agent temozolomide in patients
with newly diagnosed brain metastases from breast cancer
[29]. Temozolomide is applied orally and is well tolerated
even by elderly patients. It is widely applied in the treatment
of malignant gliomas.
3.3.9. Postoperative Followup. Patients with brain metastases
should be followed closely by a neuro-oncology/neuro-
surgery unit. Following surgery and radiotherapy, we look
after patients in our outpatient department every three
months. Herein, clinical examination and cranial MRI are
performed. If brain metastasis recurrence is noted, recran-
iotomy is discussed. Further options include radiosurgery
and chemotherapy depending on the primary tumor.
4. Conclusions
Breast cancer metastases to the neurocranium might involve
the bone (either the calvaria or the skull base), the dura
(either as a solid mass or as subdural ﬂuid collection), or the
brain parenchyma. The latter location is the far most com-
mon.Thediagnosticmethodofchoiceismagneticresonance
imaging. The treatment consists in neuronavigation-guided
microsurgical removal whenever possible. The decision
whether to operate depends mainly on the stage of the
disease, the number of brain lesions, and the performance
status of the patient. Postoperative treatment consists in
radiotherapy and/or chemotherapy depending on the pri-
mary tumor. Radiosurgery may be an alternative to surgery
or can be added to surgical treatment in selected cases.
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